Press Releases

March 9, 2023

ROME Therapeutics Appoints Keith Wilcoxen, Ph.D., as Executive Vice President, Early Development

November 10, 2022

ROME Therapeutics Demonstrates Efficacy of its Novel LINE-1 Reverse Transcriptase Inhibitor in Translational Models of Autoimmune Disease

November 2, 2022

ROME Therapeutics and Enara Bio to Host Inaugural Dark Genome Symposium Convening Industry and Academic Leaders to Catalyze Therapeutic Application of Dark Genome Research

July 18, 2022

ROME Therapeutics Appoints Industry Veteran Jeff Hatfield as Chair of Board of Directors

Reveal more

In the news

November 11, 2022

New frontier in biology: harnessing the power of the repeatome with Dennis Zaller  |  Biotech2050 podcast

October 7, 2022

ROME CEO Rosana Kapeller Named to Forbes "50 Over 50"  |  Forbes

Reveal more

Publications and presentations

May 12, 2023

Mechanism-guided quantification of LINE-1 reveals p53 regulation of both retrotransposition and transcription  |  bioRxiv

January 11, 2023

ROME Therapeutics company presentation | 41st J.P. Morgan Healthcare Conference

Reveal more